Summary: Week of 4/5/25
Biobot’s national wastewater network shows that COVID-19, influenza A & B, and RSV are decreasing in week 14 (through April 5, 2025). National hospitalizations for influenza remain the highest compared to the other respiratory viruses but continue to decrease, currently at 1.4 per 100,000 people in week 13 (through March 29, 2025). National hospitalizations for COVID-19 and RSV also decreased in week 13, currently at 1.1 and 0.1 per 100,000 people, respectively.
The Bottom Line: We are getting closer to the end of the respiratory season but flu activity remains elevated — we can expect a couple of more weeks of transmission. It’s good to remember these recommendations to stay healthy: stay current with vaccinations, consider wearing a mask in crowded areas, and if you feel unwell, minimize contact with others.
National Outlook
COVID-19
National SARS-CoV-2 concentrations are decreasing.
Influenza
National influenza A and B concentrations are decreasing.
RSV
National RSV concentrations are decreasing.
Regional
The South
COVID-19: SARS-CoV-2 concentrations are decreasing in the South.
Influenza: Influenza A and B concentrations are decreasing in the South.
RSV: RSV concentrations are decreasing in the South.
The Midwest
COVID-19: SARS-CoV-2 concentrations are decreasing in the Midwest.
Influenza: Influenza A concentrations are decreasing in the Midwest, while influenza B is holding steady.
RSV: RSV concentrations are decreasing in the Midwest.
The Northeast
COVID-19: SARS-CoV-2 concentrations are decreasing in the Northeast.
Influenza: Influenza A and B concentrations are decreasing in the Northeast.
RSV: RSV concentrations are decreasing in the Northeast.
The West
COVID-19: SARS-CoV-2 concentrations are holding steady in the West.
Influenza: Influenza A and B concentrations are decreasing in the West.
RSV: RSV concentrations are decreasing in the West.
Footnotes:
We continue to monitor the evolving H5N1 influenza virus situation, and can now test samples specifically for H5 (including H5N1) — please reach out to hello@biobot.io if interested. A quick reminder that Biobot’s influenza A assay described in this report includes the H5N1 influenza subtype, which is an influenza A virus, but does not distinguish between the different subtypes of influenza A (e.g. H5N1 vs H1N1). We will share any important updates as we have them via Bluesky and in the risk reports.
Wastewater data from Biobot Analytics for RSV, influenza, and SARS-CoV-2 are through April 5, 2025 (MMWR week 14). Clinical data for RSV, influenza, and COVID-19 are from the Centers for Disease Control and Prevention. Updates to clinical data are through March 29, 2025 (MMWR week 13).